While other pathways (e.g., JNK and STAT3) contribute to eczema, p38/NF-κB and JAK1-STAT6 were prioritized due to their clinical relevance—both are validated therapeutic targets in refractory eczema, making them ideal for evaluating MTMZM's translational potential. This evidence concerns the gene JAK1 and Eczematoid dermatitis.